Global Benign Prostatic Hyperplasia (BPH) Medication Market Insights and Forecast to 2028

Global Benign Prostatic Hyperplasia (BPH) Medication Market Insights and Forecast to 2028

Table of Contents
1 Study Coverage
1.1 Benign Prostatic Hyperplasia (BPH) Medication Product Introduction
1.2 Market by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 5-Alpha-Reductase Inhibitors
1.2.3 Beta-Blockers
1.2.4 Botanicals and Traditional Chinese Medicine
1.3 Market by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Estimates and Forecasts 2017-2028
2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Estimates and Forecasts 2017-2028
2.3 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Region
2.4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2017-2022)
2.4.2 Global Sales Benign Prostatic Hyperplasia (BPH) Medication by Region (2023-2028)
2.5 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region
2.5.1 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2017-2022)
2.5.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Manufacturers
3.1.1 Global Top Benign Prostatic Hyperplasia (BPH) Medication Manufacturers by Sales (2017-2022)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Benign Prostatic Hyperplasia (BPH) Medication in 2021
3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Manufacturers
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Manufacturers (2017-2022)
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia (BPH) Medication Revenue in 2021
3.3 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Benign Prostatic Hyperplasia (BPH) Medication Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Type
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Historical Sales by Type (2017-2022)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Forecasted Sales by Type (2023-2028)
4.1.3 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2017-2028)
4.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Historical Revenue by Type (2017-2022)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Forecasted Revenue by Type (2023-2028)
4.2.3 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Type (2017-2028)
4.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Type
4.3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Type (2017-2022)
4.3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Application
5.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Historical Sales by Application (2017-2022)
5.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Forecasted Sales by Application (2023-2028)
5.1.3 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2017-2028)
5.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application
5.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Historical Revenue by Application (2017-2022)
5.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Forecasted Revenue by Application (2023-2028)
5.2.3 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Application (2017-2028)
5.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Application
5.3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Application (2017-2022)
5.3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Price Forecast by Application (2023-2028)
6 North America
6.1 North America Benign Prostatic Hyperplasia (BPH) Medication Market Size by Type
6.1.1 North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2017-2028)
6.1.2 North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2017-2028)
6.2 North America Benign Prostatic Hyperplasia (BPH) Medication Market Size by Application
6.2.1 North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2017-2028)
6.2.2 North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2017-2028)
6.3 North America Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country
6.3.1 North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2017-2028)
6.3.2 North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Market Size by Type
7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2017-2028)
7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2017-2028)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Market Size by Application
7.2.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2017-2028)
7.2.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2017-2028)
7.3 Europe Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country
7.3.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2017-2028)
7.3.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Size by Type
8.1.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2017-2028)
8.1.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2017-2028)
8.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Size by Application
8.2.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2017-2028)
8.2.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2017-2028)
8.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region
8.3.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2017-2028)
8.3.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Benign Prostatic Hyperplasia (BPH) Medication Market Size by Type
9.1.1 Latin America Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2017-2028)
9.1.2 Latin America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2017-2028)
9.2 Latin America Benign Prostatic Hyperplasia (BPH) Medication Market Size by Application
9.2.1 Latin America Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2017-2028)
9.2.2 Latin America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2017-2028)
9.3 Latin America Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country
9.3.1 Latin America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2017-2028)
9.3.2 Latin America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Market Size by Type
10.1.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2017-2028)
10.1.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2017-2028)
10.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Market Size by Application
10.2.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2017-2028)
10.2.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2017-2028)
10.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country
10.3.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2017-2028)
10.3.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Astellas Pharma
11.1.1 Astellas Pharma Corporation Information
11.1.2 Astellas Pharma Overview
11.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Astellas Pharma Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Corporation Information
11.2.2 Eli Lilly Overview
11.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Eli Lilly Recent Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Corporation Information
11.3.2 GlaxoSmithKline Overview
11.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 GlaxoSmithKline Recent Developments
11.4 Sanofi
11.4.1 Sanofi Corporation Information
11.4.2 Sanofi Overview
11.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Sanofi Recent Developments
11.5 ADC Therapeutics
11.5.1 ADC Therapeutics Corporation Information
11.5.2 ADC Therapeutics Overview
11.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 ADC Therapeutics Recent Developments
11.6 Bayer HealthCare
11.6.1 Bayer HealthCare Corporation Information
11.6.2 Bayer HealthCare Overview
11.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Bayer HealthCare Recent Developments
11.7 Bristol-Myers Squibb
11.7.1 Bristol-Myers Squibb Corporation Information
11.7.2 Bristol-Myers Squibb Overview
11.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Bristol-Myers Squibb Recent Developments
11.8 Valeant Pharmaceuticals
11.8.1 Valeant Pharmaceuticals Corporation Information
11.8.2 Valeant Pharmaceuticals Overview
11.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Valeant Pharmaceuticals Recent Developments
11.9 Endo Pharmaceuticals
11.9.1 Endo Pharmaceuticals Corporation Information
11.9.2 Endo Pharmaceuticals Overview
11.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Endo Pharmaceuticals Recent Developments
11.10 Foresee Pharmaceuticals
11.10.1 Foresee Pharmaceuticals Corporation Information
11.10.2 Foresee Pharmaceuticals Overview
11.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Foresee Pharmaceuticals Recent Developments
11.11 Merck
11.11.1 Merck Corporation Information
11.11.2 Merck Overview
11.11.3 Merck Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Merck Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Merck Recent Developments
11.12 Novartis
11.12.1 Novartis Corporation Information
11.12.2 Novartis Overview
11.12.3 Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Novartis Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Novartis Recent Developments
11.13 Advaxis
11.13.1 Advaxis Corporation Information
11.13.2 Advaxis Overview
11.13.3 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Advaxis Recent Developments
11.14 Teva Pharmaceutical Industries
11.14.1 Teva Pharmaceutical Industries Corporation Information
11.14.2 Teva Pharmaceutical Industries Overview
11.14.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Teva Pharmaceutical Industries Recent Developments
11.15 Urologixs
11.15.1 Urologixs Corporation Information
11.15.2 Urologixs Overview
11.15.3 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Urologixs Recent Developments
11.16 Agennix
11.16.1 Agennix Corporation Information
11.16.2 Agennix Overview
11.16.3 Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Agennix Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Agennix Recent Developments
11.17 ANI Pharmaceuticals
11.17.1 ANI Pharmaceuticals Corporation Information
11.17.2 ANI Pharmaceuticals Overview
11.17.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 ANI Pharmaceuticals Recent Developments
11.18 BHR Pharma
11.18.1 BHR Pharma Corporation Information
11.18.2 BHR Pharma Overview
11.18.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 BHR Pharma Recent Developments
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Corporation Information
11.19.2 Boehringer Ingelheim Overview
11.19.3 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Boehringer Ingelheim Recent Developments
11.20 Sanpower Group
11.20.1 Sanpower Group Corporation Information
11.20.2 Sanpower Group Overview
11.20.3 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.20.4 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Sanpower Group Recent Developments
11.21 Eisai
11.21.1 Eisai Corporation Information
11.21.2 Eisai Overview
11.21.3 Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.21.4 Eisai Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.21.5 Eisai Recent Developments
11.22 Ferring
11.22.1 Ferring Corporation Information
11.22.2 Ferring Overview
11.22.3 Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.22.4 Ferring Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.22.5 Ferring Recent Developments
11.23 IO THERAPEUTICS
11.23.1 IO THERAPEUTICS Corporation Information
11.23.2 IO THERAPEUTICS Overview
11.23.3 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.23.4 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.23.5 IO THERAPEUTICS Recent Developments
11.24 LIDDS
11.24.1 LIDDS Corporation Information
11.24.2 LIDDS Overview
11.24.3 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.24.4 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.24.5 LIDDS Recent Developments
11.25 Madrigal Pharmaceuticals
11.25.1 Madrigal Pharmaceuticals Corporation Information
11.25.2 Madrigal Pharmaceuticals Overview
11.25.3 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.25.4 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.25.5 Madrigal Pharmaceuticals Recent Developments
11.26 Nymox Pharmaceutical
11.26.1 Nymox Pharmaceutical Corporation Information
11.26.2 Nymox Pharmaceutical Overview
11.26.3 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.26.4 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.26.5 Nymox Pharmaceutical Recent Developments
11.27 Spectrum Pharmaceuticals
11.27.1 Spectrum Pharmaceuticals Corporation Information
11.27.2 Spectrum Pharmaceuticals Overview
11.27.3 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.27.4 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.27.5 Spectrum Pharmaceuticals Recent Developments
11.28 Takeda Pharmaceuticals
11.28.1 Takeda Pharmaceuticals Corporation Information
11.28.2 Takeda Pharmaceuticals Overview
11.28.3 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue and Gross Margin (2017-2022)
11.28.4 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Model Numbers, Pictures, Descriptions and Specifications
11.28.5 Takeda Pharmaceuticals Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Benign Prostatic Hyperplasia (BPH) Medication Industry Chain Analysis
12.2 Benign Prostatic Hyperplasia (BPH) Medication Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Benign Prostatic Hyperplasia (BPH) Medication Production Mode & Process
12.4 Benign Prostatic Hyperplasia (BPH) Medication Sales and Marketing
12.4.1 Benign Prostatic Hyperplasia (BPH) Medication Sales Channels
12.4.2 Benign Prostatic Hyperplasia (BPH) Medication Distributors
12.5 Benign Prostatic Hyperplasia (BPH) Medication Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Benign Prostatic Hyperplasia (BPH) Medication Industry Trends
13.2 Benign Prostatic Hyperplasia (BPH) Medication Market Drivers
13.3 Benign Prostatic Hyperplasia (BPH) Medication Market Challenges
13.4 Benign Prostatic Hyperplasia (BPH) Medication Market Restraints
14 Key Findings in The Global Benign Prostatic Hyperplasia (BPH) Medication Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Benign Prostatic Hyperplasia (BPH) Medication Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of 5-Alpha-Reductase Inhibitors
Table 3. Major Manufacturers of Beta-Blockers
Table 4. Major Manufacturers of Botanicals and Traditional Chinese Medicine
Table 5. Global Benign Prostatic Hyperplasia (BPH) Medication Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2017-2022) & (KG)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region (2017-2022)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2023-2028) & (KG)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region (2023-2028)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Region (2017-2022)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2023-2028) & (US$ Million)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Region (2023-2028)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Manufacturers (2017-2022) & (KG)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Manufacturers (2017-2022)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 18. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Manufacturers (2017-2022)
Table 19. Benign Prostatic Hyperplasia (BPH) Medication Price by Manufacturers (2017-2022) &(USD/KG)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Medication Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Benign Prostatic Hyperplasia (BPH) Medication by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Medication as of 2021)
Table 22. Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Product Offered
Table 24. Date of Manufacturers Enter into Benign Prostatic Hyperplasia (BPH) Medication Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2017-2022) & (KG)
Table 27. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2023-2028) & (KG)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Type (2017-2022)
Table 29. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Type (2023-2028)
Table 30. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2017-2022) & (US$ Million)
Table 31. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2023-2028) & (US$ Million)
Table 32. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Type (2017-2022)
Table 33. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Type (2023-2028)
Table 34. Benign Prostatic Hyperplasia (BPH) Medication Price by Type (2017-2022) & (USD/KG)
Table 35. Global Benign Prostatic Hyperplasia (BPH) Medication Price Forecast by Type (2023-2028) & (USD/KG)
Table 36. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2017-2022) & (KG)
Table 37. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2023-2028) & (KG)
Table 38. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Application (2017-2022)
Table 39. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Application (2023-2028)
Table 40. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2017-2022) & (US$ Million)
Table 41. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2023-2028) & (US$ Million)
Table 42. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Application (2017-2022)
Table 43. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Application (2023-2028)
Table 44. Benign Prostatic Hyperplasia (BPH) Medication Price by Application (2017-2022) & (USD/KG)
Table 45. Global Benign Prostatic Hyperplasia (BPH) Medication Price Forecast by Application (2023-2028) & (USD/KG)
Table 46. North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2017-2022) & (KG)
Table 47. North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2023-2028) & (KG)
Table 48. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2017-2022) & (US$ Million)
Table 49. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2023-2028) & (US$ Million)
Table 50. North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2017-2022) & (KG)
Table 51. North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2023-2028) & (KG)
Table 52. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2017-2022) & (US$ Million)
Table 53. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2023-2028) & (US$ Million)
Table 54. North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2017-2022) & (KG)
Table 55. North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2023-2028) & (KG)
Table 56. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2017-2022) & (US$ Million)
Table 57. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2023-2028) & (US$ Million)
Table 58. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2017-2022) & (KG)
Table 59. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2023-2028) & (KG)
Table 60. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2017-2022) & (US$ Million)
Table 61. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2023-2028) & (US$ Million)
Table 62. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2017-2022) & (KG)
Table 63. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2023-2028) & (KG)
Table 64. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2017-2022) & (US$ Million)
Table 65. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2023-2028) & (US$ Million)
Table 66. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2017-2022) & (KG)
Table 67. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2023-2028) & (KG)
Table 68. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2017-2022) & (US$ Million)
Table 69. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2023-2028) & (US$ Million)
Table 70. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2017-2022) & (KG)
Table 71. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2023-2028) & (KG)
Table 72. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2017-2022) & (US$ Million)
Table 73. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2023-2028) & (US$ Million)
Table 74. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2017-2022) & (KG)
Table 75. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2023-2028) & (KG)
Table 76. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2017-2022) & (US$ Mil

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs